All News

Are biosimilar multi-switches an issue? real world data: DANBIO 🇩🇰 biosimilar to biosimilar switch having already had a switch prior ('previous ADAo') did not increase cessation The risk of biosimilar switching on immunogenicity is greatly overstated #ACR24 ABST1000 @RheumNow https://t.co/1yAfZrrNd0

Links:

David Liew drdavidliew ( View Tweet)
#1156 @DidemSayginMD et al finds that ~1/3 patients with myositis have comorbid fibromyalgia ➡️Presence of fibromyalgia significantly impacted patient global disease activity #acr24 @RheumNow https://t.co/u1XfqrQU1H

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Petri recommends IM triamcinolone as safer than prednisone dosing per FLOAT trial, decreased risk of fx @RheumNow #ACR24 @jhrheumatology https://t.co/vhMRdSkBAA https://t.co/novlGcss6x

Links:

Eric Dein ericdeinmd ( View Tweet)
Positive impacts of registry participation across outcomes. #ACRBest #ACR24 @RheumNow https://t.co/BgaNLfHaF1

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Late-onset asthma but earlier EGPA diagnosis? Abstract 1604 used IQVIA data to develop a machine learning model for better EGPA dx. Key predictors included eosinophilia, asthma, chronic sinusitis, multiple CXRs, skin biopsies, and GC prescriptions. @RheumNow #ACR24

Akhil Sood MD AkhilSoodMD ( View Tweet)

Sukumaran et al. Does does of IA steroid matter in knee injection? RCT 30 patients. Triamcinolone. 6-week WOMAC decrease 6% in 10mg, 10% in 20mg , 29% in 40mg @RheumNow #ACR24 Abstr#1186 https://t.co/WUYiEP5dSo

Links:

Richard Conway RichardPAConway ( View Tweet)

#1477 🔬Zasocitinib (TYK-2i) shows promise in phase IIb RCT ➡️n=290, randomised to PBO, 5/15/30mg gps 💥30mg group 📉 Rapid skin improvement @ Wk 2 ➡️Wk 12 PASI:~2X placebo (-2.5;p=0.004) 🛟Well tolerated ⬆️MDA (28 v. 12.5% p<0.05) promise for other PsA domains #ACR @RheumNow https://t.co/5GusMlVkQ4

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Exciting early data for new highly selective TYK2i zasocitinib Improved PASI skin scores (though not as much as IL23i...) Funky skin-related adverse events at higher doses, not sure what to make of that? #ACR24 @rheumnow Abstr#1477 https://t.co/CtOFsoHdBh

Links:

Mike Putman EBRheum ( View Tweet)
T2T approaches in early PsA: -STAMP trial (open label, multicenter RCT) eval early SEC (300mg+ MTX15+ 80mg steroid injection) vs SoC (MTX25+80mg steroid injection) -At week 12, 38% pts on SEC vs 17% on SoC achieved ACR50. Also did better on MDA & PASI. -No significant… https://t.co/MflI3d0FqV https://t.co/RjnzeaTyQK

Links:

Adela Castro AdelaCastro222 ( View Tweet)
How do you treat a flare of SLE with steroids? @RheumNow #ACR24

Eric Dein ericdeinmd ( View Tweet)

Petri: 5 mg prednisone or less is our standard for lupus control EULAR 23 recs - early addition of immunosuppressant and/or biologics instead to prevent steroids @RheumNow #ACR24 @jhrheumatology https://t.co/jhxEeboPu5

Links:

Eric Dein ericdeinmd ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty

Dr. John Cush RheumNow ( View Tweet)

New agent on the block: Bimekizumab IL-17A/F inhibitor Promising clinical data in SpA - what about imaging findings? Dramatic reductions in MRI activity at SI joints seen in BKZ pt, esp when compared to trajectory of PBO pt before cross-over @RheumNow #ACR24 Abst #1757 https://t.co/ACLJx5XkyN

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
At "Envisioning a Steroid Free Future" talk Angelo Gaffo at the mic: "Are there any situations you would do induction therapy for AAV without steroid?" John Stone: [pause] "No." 😄 #ACR24 @RheumNow

Mike Putman EBRheum ( View Tweet)

#1462 🔬Rx persistence in PsA; Guselkumab (GUS) v. IL17Ai 💡 GUS (n=910) persistence @ 12 months (67%) almost 2X IL-17Ai (n=2743) (50%) ⏳ Median time to discontinuation: GUS not reached v 12.3 months for IL-17Ai. 🔴Durable therapy ❓better outcomes #ACR @RheumNow https://t.co/LfA3WygNVq

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Reset the bar for remission (off steroids)!! Session #17S19 3% higher risk of organ damage for each 1mg of pred Remission possible in rheum with lower dose GC regimen and faster taper #GCStewardship #ACR24 @RheumNow @BethIWallace

Jiha Lee JihaRheum ( View Tweet)

Single centre experience of belimumab at @GSTTnhs @RheumNow #ACR24 https://t.co/c4jlEPRwen

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

In case you needed more encouragement for recombinant zoster vaccination in RA patients: it prevents herpes zoster episodes, in the real world. RA pts in KP system n=1926 vaccinated matched 1:3 with non-vaccinated - HZ reduced 60% - PHN reduced 88% #ACR24 ABST0977 @RheumNow https://t.co/BryBrlv9K5

Links:

David Liew drdavidliew ( View Tweet)
Petri on Steroids in SLE Steroid-related organ damage presents later - organ damage is higher in African-Americans Dose response for prednisone and CVD risk Each 1 mg prednisone = 3% increase risk in organ damage! #ACR24 @jhrheumatology @RheumNow https://t.co/00S1mxrXJp

Links:

Eric Dein ericdeinmd ( View Tweet)
Appreciate the conversation with Dr Ana-Maria Orbai @jhrheumatology on abstract#0600 on bimekizumab PRO data https://t.co/86J4HWKeIv @RheumNow #ACR24 https://t.co/QYqj5rKHIH

Links:

Eric Dein ericdeinmd ( View Tweet)

×